The Economic Burden of Disease in France From the National Health Insurance Perspective: The Healthcare Expenditures and Conditions Mapping Used to Prepare the French Social Security Funding Act and the Public Health Act.
Journal
Medical care
ISSN: 1537-1948
Titre abrégé: Med Care
Pays: United States
ID NLM: 0230027
Informations de publication
Date de publication:
01 09 2022
01 09 2022
Historique:
pubmed:
27
7
2022
medline:
16
8
2022
entrez:
26
7
2022
Statut:
ppublish
Résumé
Identifying the most frequently treated and the costliest health conditions is essential for prioritizing actions to improve the resilience of health systems. Healthcare Expenditures and Conditions Mapping describes the annual economic burden of 58 health conditions to prepare the French Social Security Funding Act and the Public Health Act. Annual cross-sectional study (2015-2019) based on the French national health database. National health insurance beneficiaries (97% of the French residents). All individual health care expenditures reimbursed by the national health insurance were attributed to 58 health conditions (treated diseases, chronic treatments, and episodes of care) identified by using algorithms based on available medical information (diagnosis coded during hospital stays, long-term diseases, and specific drugs). In 2019, €167.0 billion were reimbursed to 66.3 million people (52% women, median age: 42 y). The most prevalent treated diseases were diabetes (6.0%), chronic respiratory diseases (5.5%), and coronary diseases (3.2%). Coronary diseases accounted for 4.6% of expenditures, neurotic and mood disorders 3.7%, psychotic disorders 2.8%, and breast cancer 2.1%. Between 2015 and 2019, the expenditures increased primarily for diabetes (+€906 million) and neurotic and mood disorders (+€861 million) due to the growing number of patients. "Active lung cancer" (+€797 million) represented the highest relative increase (+54%) due to expenditures for the expensive drugs and medical devices delivered at hospital. These results have provided policy-makers, evaluators, and public health specialists with key insights into identifying health priorities and a better understanding of trends in health care expenditures in France.
Sections du résumé
BACKGROUND
Identifying the most frequently treated and the costliest health conditions is essential for prioritizing actions to improve the resilience of health systems.
OBJECTIVES
Healthcare Expenditures and Conditions Mapping describes the annual economic burden of 58 health conditions to prepare the French Social Security Funding Act and the Public Health Act.
DESIGN
Annual cross-sectional study (2015-2019) based on the French national health database.
SUBJECTS
National health insurance beneficiaries (97% of the French residents).
MEASURES
All individual health care expenditures reimbursed by the national health insurance were attributed to 58 health conditions (treated diseases, chronic treatments, and episodes of care) identified by using algorithms based on available medical information (diagnosis coded during hospital stays, long-term diseases, and specific drugs).
RESULTS
In 2019, €167.0 billion were reimbursed to 66.3 million people (52% women, median age: 42 y). The most prevalent treated diseases were diabetes (6.0%), chronic respiratory diseases (5.5%), and coronary diseases (3.2%). Coronary diseases accounted for 4.6% of expenditures, neurotic and mood disorders 3.7%, psychotic disorders 2.8%, and breast cancer 2.1%. Between 2015 and 2019, the expenditures increased primarily for diabetes (+€906 million) and neurotic and mood disorders (+€861 million) due to the growing number of patients. "Active lung cancer" (+€797 million) represented the highest relative increase (+54%) due to expenditures for the expensive drugs and medical devices delivered at hospital.
CONCLUSIONS
These results have provided policy-makers, evaluators, and public health specialists with key insights into identifying health priorities and a better understanding of trends in health care expenditures in France.
Identifiants
pubmed: 35880776
doi: 10.1097/MLR.0000000000001745
pii: 00005650-202209000-00003
pmc: PMC9365254
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
655-664Informations de copyright
Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–1222.
OECD, OCDE, EU, UE. Health at a Glance: Europe 2018: State of Health in the EU Cycle. Paris: OECD Publishing; Éditions OCDE; European Union; Union européenne; 2018.
Dieleman JL, Squires E, Bui AL, et al. Factors associated with increases in US health care spending, 1996-2013. JAMA. 2017;318:1668–1678.
Gini R, Francesconi P, Mazzaglia G, et al. Chronic disease prevalence from Italian administrative databases in the VALORE project: a validation through comparison of population estimates with general practice databases and national survey. BMC Public Health. 2013;13:15.
Thorpe KE. Treated disease prevalence and spending per treated case drove most of the growth in health care spending in 1987-2009. Health Aff (Millwood). 2013;32:851–858.
European Commission, Statistical Office of the European Union. HEDIC: Health Expenditures by Diseases and Conditions: 2016 Edition [Internet] . 2016. Available at: http://bookshop.europa.eu/uri?target=EUB:NOTICE:KSTC16008:EN:HTML . Accessed February 19, 2020.
Wieser S, Riguzzi M, Pletscher M, et al. How much does the treatment of each major disease cost? A decomposition of Swiss National Health Accounts. Eur J Health Econ. 2018;19:1149–1161.
Blakely T, Kvizhinadze G, Atkinson J, et al. Health system costs for individual and comorbid noncommunicable diseases: an analysis of publicly funded health events from New Zealand. PLoS Med [Internet]. 2019. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6324792/ . Accessed October 11, 2019.
Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996–2013. JAMA. 2016;316:2627–2646.
Dunn A, Whitmire B, Batch A, et al. High spending growth rates for key diseases in 2000-14 were driven by technology and demographic factors. Health Aff (Millwood). 2018;37:915–924.
Kinge JM, Sælensminde K, Dieleman J, et al. Economic losses and burden of disease by medical conditions in Norway. Health Policy. 2017;121:691–698.
Renfro S, Lindner S, McConnell KJ. Decomposing medicaid spending during health system reform and ACA expansion: evidence from oregon. Med Care. 2018;56:589–595.
Tuppin P, Rudant J, Constantinou P, et al. Value of a national administrative database to guide public decisions: from the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev Epidemiol Sante Publique. 2017;65:S149–S167.
Caisse Nationale d’Assurance Maladie. Méthode de la cartographie des pathologies et des dépenses de l’Assurance Maladie [Internet]. 2021. Available at: https://assurance-maladie.ameli.fr/etudes-et-donnees/par-theme/pathologies/cartographie-assurance-maladie/methode-cartographie-pathologies-depenses-assurance-maladie . Accessed May 8, 2022.
Caisse Nationale d'Assurance Maladie. Améliorer la qualité du système de santé et maîtriser les dépenses : les propositions de l’Assurance Maladie pour 2020 [Internet]. 2019. Available at: https://assurance-maladie.ameli.fr/etudes-et-donnees/2019-rapport-propositions-pour-2020-charges-produits . Accessed April 26, 2022.
Goldberg M, Carton M, Doussin A, et al. The REDSIAM network. Rev Epidemiol Sante Publique. 2017;65(suppl 4):S144–S148.
Rosen AB, Aizcorbe A, Highfill T, et al. Attribution of health care costs to diseases: does the method matter? Measure Mod Health Care Costs. 2016:173–210.
Larg A, Moss JR. Cost-of-illness studies: a guide to critical evaluation. Pharmacoeconomics. 2011;29:653–671.
Roehrig C. Mental disorders top the list of the most costly conditions in the United States: $201 Billion. Health Aff (Millwood). 2016;35:1130–1135.
Maura G, Billionnet C, Drouin J, et al. Oral anticoagulation therapy use in patients with atrial fibrillation after the introduction of non-vitamin K antagonist oral anticoagulants: findings from the French healthcare databases, 2011-2016. BMJ Open. 2019;9:e026645.
Wise J. Open letter raises concerns about NICE guidance on statins. BMJ. 2014;348:g3937.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63:2889–2934.
Lyall K, Croen L, Daniels J, et al. The changing epidemiology of autism spectrum disorders. Annu Rev Public Health. 2017;38:81–102.
Ha C, Chee CC. Prevalence of autism spectrum disorders. BEH. 2020;6-7:136–143.
Rousselot N, Pariente A, Mansiaux Y, et al. Impact of secured prescription implementation for zolpidem on hypnotics use in France: a time-series analysis on national data. Ann Fam Med. 2020;18:345–348.
Brouard C, Pillonel J, Boussac M, et al. French hepatitis C care cascade: substantial impact of direct-acting antivirals, but the road to elimination is still long. BMC Infect Dis. 2020;20:759.
Riley GF. Administrative and claims records as sources of health care cost data. Med Care. 2009;47(suppl 1):S51–S55.
Fuentes S, Cosson E, Mandereau-Bruno L, et al. Identifying diabetes cases in health administrative databases: a validation study based on a large French cohort. Int J Public Health. 2019;64:441–450.
Trogdon JG, Finkelstein EA, Hoerger TJ. Use of econometric models to estimate expenditure shares. Health Serv Res. 2008;43:1442–1452.
Constantinou P, Tuppin P, Fagot-Campagna A, et al. Two morbidity indices developed in a nationwide population permitted performant outcome-specific severity adjustment. J Clin Epidemiol. 2018;103:60–70.